{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI for iDFS were not estimable due to too few events having occurred.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI for iDFS were not estimable due to too few events having occurred.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"782"},{"groupId":"OG001","value":"785"}],"units":"Participants"}],"description":"iDFS = the time from randomization until the date of the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive breast cancer recurrence (an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Ipsilateral second primary invasive breast cancer, Contralateral invasive breast cancer, Distant recurrence (i.e., evidence of breast cancer in any anatomic site \\[other than the sites mentioned\\]) that has either been histologically confirmed and/or clinically/radiographically diagnosed as recurrent invasive breast cancer and Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause. Analysis used Kaplan-Meier estimates where participants with no events at the time of analysis or no post-baseline information were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered paclitaxel, 80 mg/m\\^2, IV infusion QW for maximum of 36 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2 IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated every Q2W for a maximum of 20 weeks supported with G-CSF or GM-CSF treatment.","id":"OG000","title":"Chemotherapy"},{"description":"Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.","id":"OG001","title":"Atezolizumab and Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"PD-L1-positive subpopulation included participants in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization. ITT population included all randomized participants, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)","title":"Invasive Disease-Free Survival (iDFS) in the Subpopulation With Programmed Death-ligand 1 (PD-L1) Selected Tumor Status (IC1/2/3)","type":"SECONDARY","unitOfMeasure":"months"}